Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycodone/naloxone prolonged-release for opioid-induced constipation in chronic cancer pain
ACTRN12607000493448Phase 2Completed
- Sponsor
- Mundipharma
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in cancer pain and opioid-induced constipation (OIC) comparing Oxycodone + naloxone prolonged-release with Oxycodone prolonged-release (2 arms). Primary endpoints: Bowel Function Index score, Amount of laxative medication use and 2 more. Started Aug 2007; status: completed.
02
Drugs
oxycodonenaloxone
03
Conditions
cancer painopioid-induced constipation (OIC)
Beyond the preview
Go deeper on ACTRN12607000493448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000493448.